Skip to main content

LSU Health Sciences Center New Orleans to Use OmniSeq Tumor Profiling Tech

NEW YORK (GenomeWeb) – OmniSeq announced today that it has partnered with Louisiana State University Health Sciences Center New Orleans to offer next-generation sequencing-based tumor profiling services to the institution's oncologists.

OmniSeq was spun out as a subsidiary of Roswell Park Cancer Institute in mid-2015 to provide cancer genomic testing to other organizations. It currently offers a 144-gene NGS panel called OmniSeq Comprehensive that molecularly profiles tumors to guide treatment decisions.

Under the terms of their alliance, LSU Health New Orleans will use OmniSeq Comprehensive to screen patients at its facilities, and will collaborate with OmniSeq's customers to strategize on increasing enrollment of minority and underserved populations in the Gulf South community. Additionally, LSU Health New Orleans patients will be eligible for OmniSeq's CARES financial assistance program to help with out-of-pocket costs.

Additional terms of the deal were not disclosed. 

"OmniSeq's cutting-edge technology and clinical insights will improve access to precision medicine in our underserved community, offer our physicians' guidance in the development of actionable treatment plans, and help to continue to improve the standard of care for patients at LSU Health New Orleans," Augusto Ochoa, director of LSU Health New Orleans Stanley S. Scott Cancer Center, said in a statement. "It will also allow [NCI Community Oncology Research Program] investigators to design genomics-based clinical trials tailored to Louisiana and Mississippi patients."